Effects of cannabinoid CB1 receptor antagonist rimonabant in consolidation and reconsolidation of methamphetamine reward memory in mice

Yu, Lulu; Wang, Xueyi; Zhao, Mei; Liu, Yu; Li, Yanqin; Li, Fangqiong; Wang, Xiaoyi; Xue, Yan-Xue; Lü, Lin

doi:10.1007/s00213-008-1450-y

Cited by 43 publications

(27 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is emerging evidence that the ECS may influence memory reconsolidation (see review by Diergaarde et al 2008), including drug reward-related memories. For example, Yu and colleagues (2009) recently reported that the CB1 receptor antagonist SR141716A (rimonabant) interfered with the reconsolidation of methamphetamine-induced CPP. Of course, this idea remains speculative in the absence of a defined procedure to specifically test memory reconsolidation in the present study.…”

Section: Discussionmentioning

confidence: 99%

Effects of the novel endocannabinoid uptake inhibitor, LY2183240, on fear-potentiated startle and alcohol-seeking behaviors in mice selectively bred for high alcohol preference

et al. 2010

View full text Add to dashboard Cite

Rationale Alcohol-use disorders often occur together with anxiety disorders in humans which may be partly due to common inherited genetic factors. Evidence suggests that the endocannabinoid system (ECS) is a promising therapeutic target for the treatment of individuals with anxiety and/or alcohol-use disorders. Objectives The present study assessed the effects of a novel endocannabinoid uptake inhibitor, LY2183240, on anxiety- and alcohol-seeking behaviors in a unique animal model that may represent increased genetic risk to develop comorbid anxiety and alcohol-use disorders in humans. Mice selectively bred for high alcohol preference (HAP) show greater fear-potentiated startle (FPS) than mice selectively bred for low alcohol preference (LAP). We examined the effects of LY2183240 on the expression of FPS in HAP and LAP mice and on alcohol-induced conditioned place preference (CPP) and limited-access alcohol drinking behavior in HAP mice. Results Repeated administration of LY2183240 (30 mg/kg) reduced the expression of FPS in HAP but not LAP mice when given prior to a second FPS test 48 h after fear conditioning. Both the 10 and 30 mg/kg doses of LY2183240 enhanced the expression of alcohol-induced CPP and this effect persisted in the absence of the drug. LY2183240 did not alter limited-access alcohol drinking behavior, unconditioned startle responding, or locomotor activity. Conclusions These findings suggest that ECS modulation influences both conditioned fear and conditioned alcohol reward behavior. LY2183240 may be an effective pharmacotherapy for individuals with anxiety disorders, such as post-traumatic stress disorder, but may not be appropriate for individuals with co-morbid anxiety and alcohol-use disorders.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of the novel endocannabinoid uptake inhibitor, LY2183240, on fear-potentiated startle and alcohol-seeking behaviors in mice selectively bred for high alcohol preference

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Interestingly, CB1 knockout mice are not resistant to cocaine CPP, and in fact display a facilitation of CPP acquisition following stress (Miller et al, 2008). Consolidation, retrieval and reconsolidation of methamphetamine CPP are also disrupted by CB1 antagonists (Yu et al, 2009). The antagonist effects on morphine CPP are also observed with antagonist injection into the NAc (Azizi et al, 2009), and CB1 receptors in the central amygdala may also be involved (Rezayof et al, 2011).…”

Section: Cb1 Receptorsmentioning

confidence: 99%

Presynaptic G Protein-Coupled Receptors: Gatekeepers of Addiction?

Johnson

Lovinger

2016

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Drug abuse and addiction cause widespread social and public health problems, and the neurobiology underlying drug actions and drug use and abuse is an area of intensive research. Drugs of abuse alter synaptic transmission, and these actions contribute to acute intoxication as well as the chronic effects of abused substances. Transmission at most mammalian synapses involves neurotransmitter activation of two receptor subtypes, ligand-gated ion channels that mediate fast synaptic responses and G protein-coupled receptors (GPCRs) that have slower neuromodulatory actions. The GPCRs represent a large proportion of neurotransmitter receptors involved in almost all facets of nervous system function. In addition, these receptors are targets for many pharmacotherapeutic agents. Drugs of abuse directly or indirectly affect neuromodulation mediated by GPCRs, with important consequences for intoxication, drug taking and responses to prolonged drug exposure, withdrawal and addiction. Among the GPCRs are several subtypes involved in presynaptic inhibition, most of which are coupled to the Gi/o class of G protein. There is increasing evidence that these presynaptic Gi/o-coupled GPCRs have important roles in the actions of drugs of abuse, as well as behaviors related to these drugs. This topic will be reviewed, with particular emphasis on receptors for three neurotransmitters, Dopamine (DA; D1- and D2-like receptors), Endocannabinoids (eCBs; CB1 receptors) and glutamate (group II metabotropic glutamate (mGlu) receptors). The focus is on recent evidence from laboratory animal models (and some evidence in humans) implicating these receptors in the acute and chronic effects of numerous abused drugs, as well as in the control of drug seeking and taking. The ability of drugs targeting these receptors to modify drug seeking behavior has raised the possibility of using compounds targeting these receptors for addiction pharmacotherapy. This topic is also discussed, with emphasis on development of mGlu2 positive allosteric modulators (PAMs).

show abstract

“…Later, in the absence of this agent, animals are tested for suppressed drug-seeking behavior on a test for reinstatement induced by the same stimulus used to reactivate the memory. Studies have shown that numerous agents suppress cocaine-seeking behavior in the CPP model (Miller and Marshall, 2005, Bernardi et al, 2006, Milekic et al, 2006, Valjent et al, 2006, Robinson and Franklin, 2007, Brown et al, 2008, Fricks-Gleason and Marshall, 2008, Itzhak, 2008, Wang et al, 2008, Zhai et al, 2008, Yu et al, 2009). Because phase shifts can alter the rhythms of proteins in the brain (Field et al, 2000, Yamazaki et al, 2000, Angeles-Castellanos et al, 2007), phase shifts may be similar to pharmacological agents in their ability to disrupt the reconsolidation process, which in the present experiment would be manifest as a suppression of CPP reinstatement upon subsequent testing.…”

Section: Discussionmentioning

confidence: 99%

Photoperiodic suppression of drug reinstatement

et al. 2011

View full text Add to dashboard Cite

The rewarding influence of drugs of abuse varies with time of day and appears to involve interactions between the circadian and the mesocorticolimbic dopamine systems. The circadian system is also intimately involved in measuring daylength. Thus, the present study examined the impact of changing daylength (photoperiod) on cocaine-seeking behaviors. Male Sprague Dawley rats were trained and tested on a 12L:12D light:dark schedule for cocaine-induced reinstatement of conditioned place preference (CPP) at three times of day (Zeitgeber time (ZT): 4, 12, and 20) to determine a preference score. Rats were then shifted to either shorter (6L:18D) or longer (18L:6D) photoperiods and then to constant conditions, re-tested for cocaine-induced reinstatement under each different condition, and then returned to their original photoperiod (12L:12D) and tested once more. Rats exhibited a circadian profile of preference score in constant darkness with a peak at 12h after lights-off. At both ZT4 and ZT20, but not at ZT12, shorter photoperiods profoundly suppressed cocaine reinstatement, which did not recover even after switching back to 12L:12D. In contrast, longer photoperiods did not alter reinstatement. Separate studies showed that the suppression of cocaine reinstatement was not due to repeated testing. In an additional experiment, we examined the photoperiodic regulation of tyrosine hydroxylase (TH) and dopamine transporter (DAT) proteins in drug-naive rats. These results revealed photoperiodic modulation of proteins in the prefrontal cortex and dorsal striatum, but not in the nucleus accumbens or ventral tegmental area. Together, these findings add further support to the circadian genesis of cocaine-seeking behaviors and demonstrate that drug-induced reinstatement is modulated by photoperiod. Furthermore, the results suggest that photoperiod partly contributes to the seasonal expression of certain drug-related behaviors in humans living at different latitudes and thus our findings may have implications for novel targeting of circadian rhythms in the treatment of addiction.

show abstract

Effects of cannabinoid CB1 receptor antagonist rimonabant in consolidation and reconsolidation of methamphetamine reward memory in mice

Abstract: Our findings suggest that cannabinoid CB1 receptors play a major role in methamphetamine reward memory, and cannabinoid CB1 receptor antagonists may be a potential pharmacotherapy to manage relapse associated with drug-reward-related memory.

Cited by 43 publications

References 75 publications

Effects of the novel endocannabinoid uptake inhibitor, LY2183240, on fear-potentiated startle and alcohol-seeking behaviors in mice selectively bred for high alcohol preference

Effects of the novel endocannabinoid uptake inhibitor, LY2183240, on fear-potentiated startle and alcohol-seeking behaviors in mice selectively bred for high alcohol preference

Presynaptic G Protein-Coupled Receptors: Gatekeepers of Addiction?

Photoperiodic suppression of drug reinstatement

Contact Info

Product

Resources

About